Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for \(^{177}\)Lu-DOTATATE therapy

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J. Phase 3 trial of 177 Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mansi R, Nicolas GP, Pozzo LD, Abid KA, Grouzmann E. Evaluation of a new 177Lu-labeled somatostatin analog for the treatment of tumors expressing somatostatin receptor subtypes 2 and 5. Molecules. 2020;25(18):4155.

CAS  PubMed Central  Article  Google Scholar 

Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu. EJNMMI Radiopharm Chem. 2019;4(1):1–12.

Article  Google Scholar 

Sandström M, Garske-Romań U, Granberg D, Johansson S, Widström C, Eriksson B, Sundin A, Lundqvist H, Lubberink M. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.

PubMed  Article  CAS  Google Scholar 

Hardiansyah D, Kletting P, Begum NJ, Eiber M, Beer AJ. Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based. Med Phys. 2020;48:556–68.

PubMed  Article  CAS  Google Scholar 

Ljungberg M, Sjögreen Gleisner K. Personalized dosimetry for radionuclide therapy using molecular imaging tools. Biomedicines. 2016;4(4):1–21.

Article  CAS  Google Scholar 

Ljungberg M, Sjogreen Gleisner K. 3-D image-based dosimetry in radionuclide therapy. IEEE Trans Radiat Plasma Med Sci. 2018;2(6):527–40.

Article  Google Scholar 

Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–500.

PubMed  Article  CAS  Google Scholar 

Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Sjögreen Gleisner K, Lassmann M, Flux G. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1976–88.

CAS  PubMed  Article  Google Scholar 

Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, Granberg D, Lubberink M. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56(2):177–82.

PubMed  Article  CAS  Google Scholar 

Hänscheid H, Lassmann M. Will SPECT/CT cameras soon be able to display absorbed doses? Dosimetry from single-activity-concentration measurements. J Nucl Med. 2020;61(7):1028–9.

PubMed  Article  Google Scholar 

Bardiès M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? Q J Nucl Med Mol Imaging. 2011;55(1):5–20.

PubMed  Google Scholar 

Sundlöv A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, Svensson J, Ljungberg M, Tennvall J, Sjögreen Gleisner K. Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5(1):1–19.

Article  Google Scholar 

Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, Oleinikov K, Meirovitz A, Gross DJ, Godefroy J. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7(1):1–15.

Article  Google Scholar 

Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177 Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018;5(1):1–9.

Article  Google Scholar 

Madsen MT, Menda Y, O’Dorisio TM, O’Dorisio MS. Technical note: Single time point dose estimate for exponential clearance. Med Phys. 2019;45(5):2318–24.

Article  Google Scholar 

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75–81.

PubMed  Article  CAS  Google Scholar 

Sandström M, Freedman N, Fröss-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys. 2020;7(1):1–15.

Article  Google Scholar 

Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study. Phys Med Biol. 2019;64(17):175006.

CAS  PubMed  Article  Google Scholar 

Devasia T, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A novel time-activity information sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT imaging post-177Lu-DOTATATE. J Nucl Med. 2020;62(6):1118–25.

PubMed  Google Scholar 

Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, Lundqvist H. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012;51(1):86–96.

CAS  PubMed  Article  Google Scholar 

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time- and tissue-specific dose. J Nucl Med. 2020;61(7):1030–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Howell RW, Wessels BW, Loevinger R, Watson EE, Bolch WE, Brill AB, Charkes ND, Fisher DR, Hays MT, Robertson JS, Siegel JA, Thomas SR. The MIRD perspective 1999 Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40(1):38–108.

Google Scholar 

Chauvin M, Borys D, Botta F, Bzowski P, Dabin J, Denis-Bacelar AM, Desbrée A, Falzone N, Lee BQ, Mairani A, Malaroda A, Mathieu G, McKay E, Mora-Ramirez E, Robinson AP, Sarrut D, Struelens L, Veraga Gil A, Bardiès M. Opendose: open-access resource for nuclear medicine dosimetry. J Nucl Med. 2020;61(10):1514–9.

PubMed  PubMed Central  Article  Google Scholar 

Olguin E, President B, Ghaly M, Frey E, Sgouros G. Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition. Phys Med Biol. 2020;65(23):235015.

CAS  PubMed  Article  Google Scholar 

Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212–25.

PubMed  Article  Google Scholar 

Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, Ljungberg M. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53(8):1310–25.

CAS  PubMed  Article  Google Scholar 

Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–62.

CAS  PubMed  Article  Google Scholar 

Gardner RP, Liu L. On extending the accurate and useful counting rate range of gm counter detector systems. Appl Radiat Isot. 1997;48(10–12):1605–15.

CAS  Article  Google Scholar 

Usman S, Patil A. Radiation detector deadtime and pile up: a review of the status of science. Nucl Eng Technol. 2018;50(7):1006–16.

CAS  Article  Google Scholar 

Desy A, Bouvet GF, Frezza A, Després P, Beauregard JM. Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. EJNMMI Phys. 2020;7(1):1–8.

Article  Google Scholar 

Delmon V, Rit S, Pinho R, Sarrut D. Registration of sliding objects using direction dependent B-splines decomposition. Phys Med Biol. 2013;58(5):1303–14.

CAS  PubMed  Article  Google Scholar 

Sarrut D, Badel JN, Halty A, Garin G, Perol D, Cassier P, Blay JY, Kryza D, Giraudet AL. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma. EJNMMI Phys. 2017;4(1):1–16.

Article  Google Scholar 

Sarrut D, Bardiès M, Boussion N, Freud N, Jan S, Létang J, Loudos G, Maigne L, Marcatili S, Mauxion T, Papadimitroulas P, Perrot Y, Pietrzyk U, Robert C, Schaart DR, Visvikis D, Buvat I. A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. Med Phys. 2014;41(6 Part 1):064301.

PubMed  Article  Google Scholar 

Jackson P, McIntosh L, Hofman MS, Kong G, Hicks RJ. Technical note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry. Med Phys. 2020;47(9):4332–9.

PubMed  Article  Google Scholar 

Jackson PA, Beauregard JM, Hofman MS, Kron T, Hogg A. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Med Phys. 2013;40(11): 112503.

PubMed  Article  Google Scholar 

Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238–50.

PubMed  Article  Google Scholar 

Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget J, Kotzki P, Bardiès M, Deshayes E. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res. 2018;8(103):1–13.

Google Scholar 

Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, Goldenberg DM, Bardiès M. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;15(116(SUPPL. 4)):1093–100.

Article  CAS  Google Scholar 

Hagmarker L, Svensson J, Rydén T, Van Essen M, Sundlöïv A. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60(10):1406–13.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Guerriero F, Ferrari ME, Botta F, Fioroni F, Grassi E, Versari A, Sarnelli A, Pacilio M, Amato E, Strigari L, Bodei L, Paganelli G, Iori M, Pedroli G, Cremonesi M. Kidney dosimetry in 177 Lu and 90 Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int. 2013;2013:1–12.

留言 (0)

沒有登入
gif